Tyrosine

Tyrosine

SCHEMBL180587

CSCC[C@H](N)C(=O)O.N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.71
PTGS1 P23219 2/20 0.51
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
XIAP P98170 1/20 0.51
HIF1A Q16665 2/20 0.49
KDM4E B2RXH2 1/20 0.49
USP2 O75604 1/20 0.49
EGFR P00533 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
ALOX15 P16050 1/20 0.49
HTR2A P28223 1/20 0.49
PTGS2 P35354 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TPH1 P17752 1/20 0.46
GRB2 P62993 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL28430992 1.00 SLC7A5 (0.71) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL180585 1.00 SLC7A5 (0.71) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL27531942 0.93 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL7764501 0.93 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL7764495 0.93 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1724134 0.92 SLC7A5 (0.60) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL27625516 0.92 SLC7A5 (0.60) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL28477318 0.91 SLC7A5 (0.58) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL8630269 0.91 SLC7A5 (0.58) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1585313 0.91 SLC7A5 (0.58) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117447706-A Preparation method and application of methionine-tyrosine difunctional porous material 南京工业大学 2024-01-26 CN claimed
US-20200353088-A1 PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2020-11-12 US claimed
EP-3707157-A1 PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF Auckland Uniservices Limited (NZ) 2020-09-16 EP claimed
CN-111479823-A Peptide conjugate CGRP receptor antagonist and preparation method and application thereof 奥克兰联合服务有限公司 2020-07-31 CN claimed
US-7927864-B2 Methods, kits, and compositions for detecting enzyme activity WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2011-04-19 US claimed
US-20090148851-A1 Methods, kits, and compositions for detecting enzyme activity OWEN JOHN 2009-06-11 US claimed
US-7468258-B2 Self-quenching homofluorophore compositions for detecting enzyme activity WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2008-12-23 US claimed
US-20070212696-A1 Self-quenching homofluorophore compositions for detecting enzyme activity WAKE FOREST UNIVERSITY HEALTH SCIENCES 2007-09-13 US claimed
CN-117615774-A PD-L1 binding peptides and peptide complexes and methods of use thereof 弗莱德哈钦森癌症中心 2024-02-27 CN disclosed
CN-117482911-A Preparation method and application of valine porous silicon modified graphene composite material 南京工业大学 2024-02-02 CN disclosed
CN-117447706-A Preparation method and application of methionine-tyrosine difunctional porous material 南京工业大学 2024-01-26 CN disclosed
CN-117447706-A Preparation method and application of methionine-tyrosine difunctional porous material 南京工业大学 2024-01-26 CN disclosed
CN-117447706-A Preparation method and application of methionine-tyrosine difunctional porous material 南京工业大学 2024-01-26 CN disclosed
EP-4251190-A1 PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF Fred Hutchinson Cancer Center (US) 2023-10-04 EP disclosed
EP-1144693-A3 DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE INNOGENETICS N.V. (BE) 2001-11-28 EP disclosed
EP-1144693-A2 DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE INNOGENETICS N.V. (BE) 2001-10-17 EP disclosed
WO-2001004358-A2 DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE INNOGENETICS N.V. (BE) 2001-01-18 WO disclosed
US-5239061-A MODIFIED HUMAN HEMOGLOBIN, BLOOD SUBSTITUTES CONTAINING THE SAME, AND VECTORS FOR EXPRESSING THE MODIFIED HEMOGLOBIN RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-08-24 US disclosed
WO-1991019505-A1 MODIFIED HUMAN HEMOGLOBIN, BLOOD SUBSTITUTES CONTAINING THE SAME, AND VECTORS FOR EXPRESSING THE MODIFIED HEMOGLOBIN RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-12-26 WO disclosed
US-5062935-A METHOD OF VAPORIZING A SAMPLE SUBSTANCE BRUKER-FRANZEN ANALYTIK GMBH (DE) 1991-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200353088-A1 PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF CALCRL, CALCR, GRPR SLC7A5 1069/4885PTGS1 1469/4885ALPI 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.